Skip to main content

  • Decreasing pacemaker implantation rates with Evolut supra-annular transcatheter aortic valves in a large real-world registry

    • Posted: 12/19/2024
    • Author:

      James E. Harvey, Rishi Puri, Kendra J. Grubb, Steven J. Yakubov, Paul D. Mahoney, Hemal Gada, Megan Coylewright, Marie-France Poulin, Stanley J. Chetcuti, Paul Sorajja, Joshua D. Rovin, Ruth Eisenberg and Michael J. Reardon

    • 2024NewsCRM

    Abstract

    Background

    Permanent pacemaker implantation (PPI) rates following transcatheter aortic valve replacement (TAVR) remain a concern. We assessed the PPI rates over time in patients implanted with an Evolut supra-annular, self-expanding transcatheter valve from the US STS/ACC TVT Registry.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details